hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate LONDON, UNITED KINGDOM--(Marketwired - Feb 21, 2017) -  hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, notes the announcement from the US...

hVIVO to Present at the 2016 BIO Investor Forum LONDON, UNITED KINGDOM--(Marketwired - Oct 13, 2016) - hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, today announced that it will be presenting at the 2016...